title: High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?
authors.affiliation: a Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne , Victoria , Australia.
authors.forename: Carrie
authors.initials: C
authors.lastname: van der Weyden
authors.affiliation: a Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne , Victoria , Australia.|b Division of Cancer Medicine, Peter MacCallum Cancer Centre and University of Melbourne , Melbourne, Victoria , Australia.
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D009420:Nervous System; D009965:Orphan Drug Production; D013852:Thiotepa / Q000627:therapeutic use*; D019172:Transplantation Conditioning
chemical_list: D013852:Thiotepa